Alcobra Ltd. has selected Premier Research as its CRO to conduct a Phase III study of MG01CI as a potential treatment for adults with Attention Deficit Hyperactivity Disorder (ADHD).
 
“We are delighted to partner with Premier Research as we embark upon our most important clinical study to date. Premier Research has extensive knowledge and expertise regarding central nervous system (CNS) clinical trials, having conducted more than 150 CNS studies over the past five years, including numerous advanced stage ADHD trials,” said Dr. Jonathan Rubin, chief medical officer of Alcobra Ltd. “Their experience, including site selection, clinical trial design and expertise in clinical trial operations, should prove invaluable as we work diligently to navigate through the FDA approval process to seek an adult ADHD indication for MG01CI.”